Drug
Idarubicin clinical trials
Also written Idamycin, Zavedos, IMI-30 and SC-33428.
Keep track of what changes. Save the Idarubicin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
111 studies that test it; most in 1998 (8)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1994 | 2 |
| 1995 | 2 |
| 1996 | 3 |
| 1997 | 1 |
| 1998 | 8 |
| 1999 | 1 |
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 4 |
| 2004 | 4 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 3 |
| 2009 | 6 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 8 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 3 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Leukemia
- 10
Who runs them
Industry 5 · Other 106
M.D. Anderson Cancer Center (15) · National Cancer Institute (NCI) (6) · Fred Hutchinson Cancer Center (6) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Children's Oncology Group (4) · Institute of Hematology & Blood Diseases Hospital, China (3) · St. Jude Children's Research Hospital (2) · Massachusetts General Hospital (2)
Often tested with
Tested in the same studies.
Cytarabine (66) · Etoposide (12) · Daunorubicin (11) · Dexamethasone (11) · Venetoclax (11) · Filgrastim (11) · Cyclophosphamide (10) · Methotrexate (10)
Studies
Open first, then newest update. How each study uses Idarubicin is read from its arms, and is right about nine times in ten.
Testing it · 111
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT00801489Written as Idarubicin
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingPhase 1Fred Hutchinson Cancer CenterNCT04375631Written as Idarubicin
- UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLRecruitingEarly Phase 1Baylor College of MedicineNCT07059975Written as Idarubicin Hydrochloride
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as Idarubicin
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06265545Written as Daunorubicin/ Idarubicin /Mitoxantrone
- Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid CancerRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07046078Written as Idarubicin
- Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CRRecruitingPhase 2/3University Hospital, AngersNCT02416388Written as Idarubicin
- Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04047641Written as Idarubicin
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02115295Written as Idarubicin
- Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).RecruitingPhase 4Fujian Medical University Union HospitalNCT07561892Written as daunomycin/Idarubicin+ Silybinin
- VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm TrialRecruitingPhase 2Beijing 302 HospitalNCT07514832Written as Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06221683Written as Idarubicin Hydrochloride
- Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingPhase 2Second Affiliated Hospital of Guangzhou Medical UniversityNCT06492408Written as ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
- Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingPhase 2Second Affiliated Hospital of Guangzhou Medical UniversityNCT06492421Written as ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
- Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDSNot yet recruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06050941Written as idarubicin
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingPhase 2/3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05313958Written as Idarubicin
- Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)RecruitingNot applicableFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT03390387Written as Idarubicin
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingPhase 2/3St. Jude Children's Research HospitalNCT03117751Written as Idarubicin
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid LeukemiaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04190550Written as Idarubicin Hydrochloride
- Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingPhase 1/2University of Southern CaliforniaNCT03330821Written as Idarubicin
See all 111 studies that test Idarubicin →
Given in every arm · 63 — Idarubicin is usual care beside what is tested
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaRecruitingPhase 2OHSU Knight Cancer InstituteNCT07228273Written as Idarubicin
- Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07604233Written as Idarubicin
- Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT03214562Written as Idarubicin
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 2St. Jude Children's Research HospitalNCT05955261Written as Idarubicin Hydrochloride
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1Kura Oncology, Inc.NCT06001788Written as Idarubicin
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1RecruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT06744504Written as idarubicin
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersRecruitingPhase 2M.D. Anderson Cancer CenterNCT03589729Written as Idarubicin
- Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT06928662Written as Idarubicin
- Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction TherapyRecruitingNot applicableAffiliated Hospital of Nantong UniversityNCT06643962Written as Idarubincin
- Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT MutationRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06316960Written as Idarubicin Hydrochloride
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsActive, not recruitingPhase 1Fred Hutchinson Cancer CenterNCT06034470Written as Idarubicin
- BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid LeukemiaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04214249Written as Idarubicin Hydrochloride
- Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid LeukemiaTerminatedPhase 1Northwestern UniversityNCT04250051Written as Idarubicin
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaCompletedPhase 3Technische Universität DresdenNCT02688140Written as Idarubicin
- Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT06497062Written as idarubicin/daunorubicin
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT03164057Written as Idarubicin
- Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AMLCompletedPhase 3Arog Pharmaceuticals, Inc.NCT03250338Written as Idarubicin
- Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)CompletedPhase 2PETHEMA FoundationNCT04107727Written as Idarubicin
- Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic LeukemiaActive, not recruitingPhase 3Children's Oncology GroupNCT02339740Written as Idarubicin
- Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep RCompletedPhase 2City of Hope Medical CenterNCT00534469Written as idarubicin
Showing 20 of 63.
As the comparator · 10 — what is tested is compared with Idarubicin
- Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia PatientsRecruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07132684Written as Daunorubicin/Idarubicin
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07486479Written as Idarubicin
- Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLRecruitingPhase 2Guangdong Provincial People's HospitalNCT06451861Written as Anthracyclines or anthraquinones
- HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AMLActive, not recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06744556Written as Idarubicin
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Idarubicin
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedPhase 3Goethe UniversityNCT02881086Written as Idarubicin
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedTerminatedPhase 3Gilead SciencesNCT04778397Written as Idarubicin
- Phase III Trial in Acute Promyelocytic Leukemia PatientsCompletedPhase 3Gruppo Italiano Malattie EMatologiche dell'AdultoNCT00482833Written as idarubicin
- HLA-mismatched Microtransplantation for High Risk Acute Myeloid LeukemiaStatus unknownPhase 3The Affiliated Hospital of the Chinese Academy of Military Medical SciencesNCT01484171Written as idarubicin
- Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell TransplantationCompletedPhase 2/3Nantes University HospitalNCT01015196Written as Zavedos
Codes
What other systems call Idarubicin · ClinicalTrials.gg INT008453
- MeSH (NLM) D015255IdarubicinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ZRP63D75JWIDARUBICINConfirmed FDA, NLM, Wikidata
- RxNorm 5650Confirmed FDA, Wikidata
- Wikidata Q1063862idarubicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C562IdarubicinOne source FDA
- DrugBank DB01177One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015255 | Idarubicin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ZRP63D75JW | IDARUBICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 5650 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1063862 | idarubicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C562 | Idarubicin | One source FDA |
| DrugBank | DB01177 | — | One source Wikidata |
Also registered as idarubicin hydrochloride (UNII 5VV3MDU5IE · RxNorm 82124).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.